Insightec has announced that Humana is now the fifth national U.S. payer to cover the company's focused ultrasound treatment for medication-refractory essential tremor.
For patients whose tremor does not respond to medications, MR-guided focused ultrasound is performed in a single, outpatient procedure. Insightec highlighted that patients show immediate improvement of tremor in the treated hand with minimal or no complications. The company in 2022 received approval from the U.S. Food and Drug Administration to treat essential tremor using Insightec's Exablate Neuro platform.
Humana joins the following national payers to cover this treatment: Cigna, Anthem, Aetna, and Blue Cross Blue Shield Association. These payers started covering the treatment between 2018 and 2023. Also, focused ultrasound treatment for medication-refractory essential tremor is covered by Medicare in all 50 states.